Hepatic impairment trials are generally included as part of the clinical development of a drug. This whitepaper, based on years of experience executing hepatic trials, provides practical information for pharma and biotech professionals. In this whitepaper, you’ll gain knowledge of:
- Similarities and differences between FDA and EMEA guidance on hepatic trials.
- Categorization standards for hepatic trials.
- Solutions and guidance for those conducting hepatic trials.